• International commercial leader Erin Federman joins the executive leadership team and will lead the company’s global commercial strategy as of 1st May.

​

• Erin Federman has over two decades of experience driving growth across the life sciences sector.

​

• “We are thrilled to welcome Erin to QuantiLight at this exciting stage of our journey” said Corentin Gondrand, CEO at QuantiLight. “Her deep expertise in launch strategy, market access, and global commercialization will be instrumental as we scale and bring our diagnostic solution into everyday clinical practice.”

​

Heidelberg, Germany - 1st May 2025

​

QuantiLight, a pioneering developer of portable, point-of-care blood testing technology, has appointed Erin Federman as its new Chief Commercial Officer (CCO). Based in Frankfurt, Erin joins the executive leadership team and take charge of the company’s global commercial strategy as it prepares to bring its diagnostic platform to market.

​

Erin brings more than 20 years of commercial leadership experience across the life sciences sector. Most recently, she served as Vice President and Global Commercial Head, Specialty Care at STADA, where she led the transformation of the company’s biosimilars business—doubling both revenue and profit over three years. She built a global commercial organization from the ground up, established pricing and access capabilities, and successfully led multi-region launches across Europe, MENA, and Eurasia.

​

Prior to STADA, Erin held senior global roles at Novo Nordisk, where she led portfolio strategy and global marketing for the company’s insulin franchise. During this time, she also contributed to initiatives focused on Time in Range and glucose monitoring in type 2 diabetes—deepening her exposure to digital health metrics and the evolving role of data in chronic disease management.

She also served as VP and Commercial Head of Biologics Europe at Mylan, where she helped build a new biosimilars business unit. Earlier in her career, Erin held commercial and strategic roles at Boehringer Ingelheim, Pfizer, Karl Storz, and Fujifilm SonoSite, spanning both upstream and downstream functions in pharmaceuticals and medical devices.

​

Erin’s experience also includes leading commercial partnerships and alliance management with strategic partners such as Alvotech, Biocon, Fujifilm Kyowa Kirin, Gedeon Richter/Helm, Lupin, and mAbxience.

​

She holds an MBA in Marketing & International Business from the University of Cincinnati and completed executive education in Finance at Harvard Business School. Erin previously served as Chair of the Market Access Committee for Medicines for Europe and is a frequent speaker on commercialization, access strategy, and patient-centric innovation.

​